Related references
Note: Only part of the references are listed.Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases
Jens Sperling et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Liver-Directed Therapies: Does It Make Sense in the Current Therapeutic Strategy for Patients With Confined Liver Colorectal Metastases?
E. Seront et al.
CLINICAL COLORECTAL CANCER (2012)
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
Edward Chu
CLINICAL COLORECTAL CANCER (2012)
A simple procedure for estimation of total body surface area and determination of a new value of Meeh's constant in rats
E. Gouma et al.
LABORATORY ANIMALS (2012)
An update on chemotherapy of colorectal liver metastases
Chen-Chen Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
The molecular biology of colorectal carcinoma and its implications: A review
Sanjay Harrison et al.
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND (2011)
The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization
Zohar Habot-Wilner et al.
ACTA OPHTHALMOLOGICA (2010)
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
Gianluca Masi et al.
LANCET ONCOLOGY (2010)
Bevacizumab Suppression of Establishment of Micrometastases in Experimental Ocular Melanoma
Hua Yang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel
B. Nordlinger et al.
ANNALS OF ONCOLOGY (2009)
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
A. Okines et al.
BRITISH JOURNAL OF CANCER (2009)
New approaches and targets in advanced colorectal cancer
Teresa Macarulla et al.
EUROPEAN JOURNAL OF CANCER (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prevention and Treatment of Corneal Neovascularization: Comparison of Different Doses of Subconjunctival Bevacizumab with Corticosteroid in Experimental Rats
Mohammad Naser Hashemian et al.
OPHTHALMIC RESEARCH (2009)
Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model
Miltiadis Papathanassiou et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation
D. Balin-Gauthier et al.
BRITISH JOURNAL OF CANCER (2008)
Regional chemotherapy for liver-limited metastatic colorectal cancer
Derek G. Power et al.
CLINICAL COLORECTAL CANCER (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells
Fan Fan et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn
Efdal Yoeruek et al.
ACTA OPHTHALMOLOGICA (2008)
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
J. Tol et al.
ANNALS OF ONCOLOGY (2008)
Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis
Hamid Hosseini et al.
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2007)
Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy
Rene Adam et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The effects of the subconjunctival injection of bevacizumab (Avastin®) on angiogenesis in the rat cornea
Luiz F. M. Barros et al.
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS (2007)
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
Roberta P. A. Manzano et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2007)
Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis
Felix Bock et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2007)
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group
Bernard Nordlinger et al.
EUROPEAN JOURNAL OF CANCER (2007)
Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology
Anke C. Reinacher-Schick et al.
INTERNIST (2007)
Outcome of metastatic colorectal cancer: Analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach
Elisa Sperti et al.
DISEASES OF THE COLON & RECTUM (2006)
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Eric Van Cutsem et al.
EUROPEAN JOURNAL OF CANCER (2006)
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study)
M Hebbar et al.
CANCER INVESTIGATION (2006)
OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic
Girolamo Ranieri et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer
M Ducreux et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer:: A randomized GERCOR study
C Tournigand et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: comparative results with cisplatin using a rabbit VX2 tumor model
R Dzodic et al.
ANTI-CANCER DRUGS (2004)
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
RM Goldberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours
M Ng et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2004)
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs
F Ciardiello et al.
EUROPEAN JOURNAL OF CANCER (2003)
The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors
CA Ritter et al.
SEMINARS IN ONCOLOGY (2003)
An update on hepatic arterial infusion chemotherapy for colorectal cancer
AD Cohen et al.
ONCOLOGIST (2003)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
